Curaleaf Holdings, Inc. (CSE:CURA) (OTCQX: CURLF) has purchased EMMAC Life Sciences
Transaction Details: Under the deal, Curaleaf agreed to pay $50 million in cash and 17.5 million in stock — worth roughly $260 million. The company plans to pay additional consideration to EMMAC stakeholders upon the achievement of particular performance milestones.
To boost its European footprint further, while holding its EMMAC investment, Curaleaf has created Curaleaf International Holdings Limited on the island of Guernsey.
Powered by WPeMatico